Expand all sections

Nemolizumab

Extended indication

Atopic Dermatitis; Prurigo (jeuk)
Therapeutic value

No judgement

Product

Active substance

Nemolizumab
Domain

Chronic immune diseases
Main indication

Skin diseases
Extended indication

Atopic Dermatitis; Prurigo (jeuk)
Manufacturer

Galderma
Route of administration

Subcutaneous
Therapeutical formulation

Injection

Registration

Registration route

Centralised (EMA)
Orphan drug

No

Therapeutic value

Therapeutic value

No judgement
Frequency of administration

1 times a month
Dosage per administration

0,1-0,5-2,0 mg/kg
References 
Bron: Ruzicka et al, N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490
Additional remarks 
Toediening 1 maal per 4 weken

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost

< 15,000.00
Additional remarks 
Vergelijkbaar met Dupilumab, zal de concurrentie aan moeten gaan wat de prijs nog zou kunnen drukken.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.